P
Prakash Radhakrishnan
Researcher at Eppley Institute for Research in Cancer and Allied Diseases
Publications - 56
Citations - 1630
Prakash Radhakrishnan is an academic researcher from Eppley Institute for Research in Cancer and Allied Diseases. The author has contributed to research in topics: Pancreatic cancer & Cancer. The author has an hindex of 17, co-authored 45 publications receiving 1141 citations. Previous affiliations of Prakash Radhakrishnan include University of Nebraska Medical Center & University of Nebraska–Lincoln.
Papers
More filters
Journal ArticleDOI
Immature truncated O-glycophenotype of cancer directly induces oncogenic features
Prakash Radhakrishnan,Sally Dabelsteen,Frey Brus Madsen,Chiara Francavilla,Katharina L. Kopp,Catharina Steentoft,Sergey Y. Vakhrushev,Jesper V. Olsen,Lars Hansen,Eric P. Bennett,Anders Woetmann,Guangliang Yin,Longyun Chen,Haiyan Song,Mads Bak,Ryan A. Hlady,Staci L. Peters,Rene Opavsky,Christenze Thode,Klaus Qvortrup,Katrine T. Schjoldager,Henrik Clausen,Michael A. Hollingsworth,Hans H. Wandall +23 more
TL;DR: It is demonstrated, with the use of well-defined cell systems generated by precise gene editing, that the aberrant O-glycophenotype by itself induces oncogenic features with enhanced growth and invasion, and further provides support for immunotherapeutic strategies that target aberrant o-glycans.
Journal ArticleDOI
Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis
TL;DR: Understanding of recent advances in research about the role of fibrosis in pancreatic cancer progression is summarized, with particular emphasize on the involvement of fibrotic machineries such as wound healing, extra cellular matrix degradation, and epithelial-to-mesenchymal transition.
Journal ArticleDOI
Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia
Surendra K. Shukla,Teklab Gebregiworgis,Vinee Purohit,Vinee Purohit,Nina V. Chaika,Venugopal Gunda,Prakash Radhakrishnan,Kamiya Mehla,Iraklis I. Pipinos,Robert Powers,Fang Yu,Pankaj K. Singh +11 more
TL;DR: The studies demonstrate that the cachectic phenotype is in part due to metabolic alterations in tumor cells, which can be reverted by a ketogenic diet, causing reduced tumor growth and inhibition of muscle and body weight loss.
Journal ArticleDOI
MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer
Nina V. Chaika,Teklab Gebregiworgis,Michelle E. Lewallen,Vinee Purohit,Prakash Radhakrishnan,Xiang Liu,Bo Zhang,Kamiya Mehla,Roger B. Brown,Thomas C. Caffrey,Fang Yu,Keith R. Johnson,Robert Powers,Michael A. Hollingsworth,Pankaj K. Singh +14 more
TL;DR: It is demonstrated that MUC1, a large, type I transmembrane protein that is overexpressed in several carcinomas including pancreatic adenocarcinoma, modulates cancer cell metabolism to facilitate growth properties of cancer cells.
Journal ArticleDOI
Altered glycosylation in cancer: A promising target for biomarkers and therapeutics.
TL;DR: The fundamental role of glycans in regulating tumorigenesis and tumor progression is discussed and insights into the influence of glycosylation in the current tactics of targeted therapies in the clinical setting are provided.